indication

Mood Disorders

Competitive landscape projected to Resilience Training (RT)’s launch window

as of 2026-07-01
Competitive set
3
3 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
21 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
Resilience Training (RT) launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 33 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 31 trial
OwnerAstraZeneca
Protection—
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
—1 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041

Market size

prevalence as a range, not a number